Full Text View
Tabular View
No Study Results Posted
Related Studies
L-BLP25 (Stimuvax) in Rectal Cancer (SPRINT)
This study is currently recruiting participants.
Verified January 2012 by Merck KGaA
Study NCT01507103   Information provided by Merck KGaA

First Received on January 6, 2012.   No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Rectal Cancer
Additional conditions recognized in this trial
Rectal Neoplasms
More general conditions related to this trial
Colorectal Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases
Interventions listed in this trial
Chemoradiation Therapy
Cyclophosphamide
L-BLP25
Additional drug interventions recognized in this trial
Antineoplastic Agents
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Immunologic Factors
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Merck KGaA


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services